Asia-Pacific Radiotherapy Market Overview
Asia-Pacific radiotherapy market is expected to observe the highest growth rate during the forecast period owing to a number of factors comprising refining healthcare infrastructure and supportive government activities.
In the present global state where the number of people bearing with different types of cancer is on the growth, the applications of new and upgraded as well as conventional forms of radiotherapy are enormous. The supreme important necessity requiring the development of improved and progressively precise radiation therapy is the requirement to exactly hit only the affected tumor using the radiation beam and avoid harming the surrounding tissue.
Increase in the number of elderly population, technological innovations in radiotherapy products, rising conferences driving investments in radiotherapy, growing incidence of cancer incidences and mounting acceptance of radiotherapy devices and procedures will majorly drive the radiotherapy market. Though the absence of trained personnel to perform the therapy, practiced alternative therapy, its incapability to be used for metastasis state of cancer and side effects associated with the treatment restrained the market growth.
Asia-Pacific Radiotherapy Market Forecast Report (2018-2023)
Asia-Pacific Radiotherapy Market was worth $1.28 billion in 2018 and estimated to be growing at a CAGR of 6.82%, to reach $1.79 billion by 2023.
Asia-Pacific Radiotherapy Market Segmentation
The Asia-Pacific radiotherapy market is segmented on the basis of type into External beam radiation therapy, internal beam radiation therapy, and systemic radiation therapy. External beam radiation therapy is sub-segmented into Intensity-modulated radiation therapy (IMRT), Image-guided radiation therapy (IGRT), Tomotherapy, Stereotactic radiosurgery, Stereotactic body radiation therapy, and Proton therapy. Based on the application the market is segregated into Skin & Lip Cancer, Head & Neck Cancer, Breast Cancer, Prostate Cancer, Cervical Cancer, Lung Cancer, and Spine Cancer. On the basis of equipment type market is bifurcated into Linear accelerators, Radiation therapy simulators and Treatment planning systems. The prostate cancer application segment is estimated to hold the largest share in both external beam radiotherapy market along with internal radiotherapy market.
Based on geography the market is analyzed under various regions namely, China, India, Japan, South Korea, and Australia. China is dominating the Asia-Pacific region radiotherapy market due to a large number of elderly population in the country and is expected to continue its dominance.
Key Developments in the Market
Major Players:
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Type
5.1.1 External Beam Radiation Therapy
5.1.1.1 Intensity-Modulated Radiation Therapy (IMRT)
5.1.1.2 Image-Guided Radiation Therapy (IGRT)
5.1.1.3 Tomotherapy
5.1.1.4 Stereotactic Radiosurgery
5.1.1.5 Stereotactic body Radiation Therapy
5.1.1.6 Proton Therapy
5.1.2 Internal Beam Radiation Therapy
5.1.3 Systemic Radiation Therapy
5.2 By Application
5.2.1 Skin & Lip Cancer
5.2.2 Head & Neck Cancer
5.2.3 Breast Cancer
5.2.4 Prostate Cancer
5.2.5 Cervical Cancer
5.2.6 Lung Cancer
5.2.7 Spine Cancer
5.3 By Equipment Type
5.3.1 Linear Accelerators
5.3.2 Radiation Therapy Simulators
5.3.3 Treatment Planning Systems
6. Geographical Analysis
6.3 Asia-Pacific
6.1 Introduction
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7. Pipeline Product Analysis
7.1 Overview
7.2 Pipeline Development Landscape
7.3 Molecular Targets in the Pipeline
7.4 Clinical Trials
7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.
8. Strategic Analysis
8.1 PESTLE analysis
8.1.1 Political
8.1.2 Economic
8.1.3 Social
8.1.4 Technological
8.1.5 Legal
8.1.6 Environmental
8.2 Porter’s Five analysis
8.2.1 Bargaining Power of Suppliers
8.2.2 Bargaining Power of Consumers
8.2.3 Threat of New Entrants
8.2.4 Threat of Substitute Products and Services
8.2.5 Competitive Rivalry within the Industry
9. Market Leaders' Analysis
9.1 Nordion Inc.
9.1.1 Overview
9.1.2 Product Analysis
9.1.3 Strategic Evaluation and Operations
9.1.4 Financial analysis
9.1.5 Legal issues
9.1.6 Recent Developments
9.1.7 SWOT analysis
9.1.8 Analyst View
9.2 RaySearch Laboratories AB
9.3 Ion Beam Applications SA
9.4 C. R. Bard Inc.
9.5 Mevion Medical Systems Inc.
9.6 Varian Medical Systems Inc.
9.7 IsoRay Medical Inc.
9.8 Elekta AB
9.9 Accuray Incorporated
9.10 Mitsubishi Electric Corporation
10. Competitive Landscape
10.1 Market share analysis
10.2 Merger and Acquisition Analysis
10.3 Agreements, collaborations and Joint Ventures
10.4 New Product Launches
11. Expert Opinions
11.1 Market Outlook
11.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
